These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 27568836)

  • 21. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.
    Hideshima T; Bradner JE; Wong J; Chauhan D; Richardson P; Schreiber SL; Anderson KC
    Proc Natl Acad Sci U S A; 2005 Jun; 102(24):8567-72. PubMed ID: 15937109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Carbon monoxide released by CORM-3 inhibits human platelets by a mechanism independent of soluble guanylate cyclase.
    Chlopicki S; Olszanecki R; Marcinkiewicz E; Lomnicka M; Motterlini R
    Cardiovasc Res; 2006 Jul; 71(2):393-401. PubMed ID: 16713591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of ubiquitin proteasome function prevents monocrotaline-induced pulmonary arterial remodeling.
    Zhu Y; Wu Y; Shi W; Wang J; Yan X; Wang Q; Liu Y; Yang L; Gao L; Li M
    Life Sci; 2017 Mar; 173():36-42. PubMed ID: 28212825
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Levobupivacaine differentially suppresses platelet aggregation by modulating calcium release in a dose-dependent manner.
    Liou JT; Mao CC; Liu FC; Lin HT; Hung LM; Liao CH; Day YJ
    Acta Anaesthesiol Taiwan; 2012 Sep; 50(3):112-21. PubMed ID: 23026170
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of rat platelet aggregation by mycalolide-B, a novel inhibitor of actin polymerization with a different mechanism of action from cytochalasin-D.
    Sugidachi A; Ogawa T; Asai F; Saito S; Ozaki H; Fusetani N; Karaki H; Koike H
    Thromb Haemost; 1998 Mar; 79(3):614-9. PubMed ID: 9531051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proteasome inhibitor prevents experimental arterial thrombosis in renovascular hypertensive rats.
    Ostrowska JK; Wojtukiewicz MZ; Chabielska E; Buczko W; Ostrowska H
    Thromb Haemost; 2004 Jul; 92(1):171-7. PubMed ID: 15213858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proteasome inhibition boosts autophagic degradation of ubiquitinated-AGR2 and enhances the antitumor efficiency of bevacizumab.
    Wang D; Xu Q; Yuan Q; Jia M; Niu H; Liu X; Zhang J; Young CY; Yuan H
    Oncogene; 2019 May; 38(18):3458-3474. PubMed ID: 30647455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Specific inhibition of ADP-induced platelet aggregation by clopidogrel in vitro.
    Weber AA; Reimann S; Schrör K
    Br J Pharmacol; 1999 Jan; 126(2):415-20. PubMed ID: 10077233
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
    Jakubowski JA; Payne CD; Li YG; Farid NA; Brandt JT; Small DS; Salazar DE; Winters KJ
    Thromb Haemost; 2008 Jan; 99(1):215-22. PubMed ID: 18217157
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy.
    Guthikonda S; Mangalpally K; Vaduganathan M; Patel R; Delao T; Bergeron AL; Dong JF; Lev EI; Kleiman NS
    Thromb Haemost; 2008 Jul; 100(1):83-9. PubMed ID: 18612542
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tanshinone IIA, a major component of Salvia milthorriza Bunge, inhibits platelet activation via Erk-2 signaling pathway.
    Maione F; De Feo V; Caiazzo E; De Martino L; Cicala C; Mascolo N
    J Ethnopharmacol; 2014 Sep; 155(2):1236-42. PubMed ID: 25038434
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blunted inhibition by insulin of agonist-stimulated calcium, pH and aggregatory responses in platelets from hypertensive patients.
    Touyz RM; Schiffrin EL
    J Hypertens; 1994 Nov; 12(11):1255-63. PubMed ID: 7868873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Doubling the clopidogrel dose in patients with reduced responsiveness to the standard dose is associated with a limited effectiveness as evaluated by impedance aggregometry.
    Stellbaum C; Ayral Y; Morguet A; Schultheiss HP; Rauch U
    Cardiovasc Revasc Med; 2012; 13(3):159-66. PubMed ID: 22503564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
    Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Profound activity of the anti-cancer drug bortezomib against Echinococcus multilocularis metacestodes identifies the proteasome as a novel drug target for cestodes.
    Stadelmann B; Aeschbacher D; Huber C; Spiliotis M; Müller J; Hemphill A
    PLoS Negl Trop Dis; 2014 Dec; 8(12):e3352. PubMed ID: 25474446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amifostine, a reactive oxigen species scavenger with radiation- and chemo-protective properties, inhibits in vitro platelet activation induced by ADP, collagen or PAF.
    Porta C; Maiolo A; Tua A; Grignani G
    Haematologica; 2000 Aug; 85(8):820-5. PubMed ID: 10942928
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective activation of the prostaglandin E2 receptor subtype EP2 or EP4 leads to inhibition of platelet aggregation.
    Kuriyama S; Kashiwagi H; Yuhki K; Kojima F; Yamada T; Fujino T; Hara A; Takayama K; Maruyama T; Yoshida A; Narumiya S; Ushikubi F
    Thromb Haemost; 2010 Oct; 104(4):796-803. PubMed ID: 20664890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of the aggregation responses of camel platelets.
    Al Ghumlas AK; Gader AG
    Vet Clin Pathol; 2013 Sep; 42(3):307-13. PubMed ID: 23919654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enantioselective synthesis of adamantylalanine and carboranylalanine and their incorporation into the proteasome inhibitor bortezomib.
    de Bruin G; Mock ED; Hoogendoorn S; van den Nieuwendijk AM; Mazurek J; van der Marel GA; Florea BI; Overkleeft HS
    Chem Commun (Camb); 2016 Mar; 52(21):4064-7. PubMed ID: 26894389
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The antiplatelet activity of camel urine.
    Alhaidar A; Abdel Gader AG; Mousa SA
    J Altern Complement Med; 2011 Sep; 17(9):803-8. PubMed ID: 21854200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.